Exercise of Options and Total Voting Rights
20 October 2026
Aminex plc
("Aminex" or "the Company")
Exercise of Options and Total Voting Rights
Aminex announces that it has issued a total of 6,000,000 ordinary shares of €0.001 each (the "Option Shares") following the exercise of an option by Thomas Mackay, Non-executive Director, under the Aminex PLC Restricted Share Plan approved by shareholders in July 2020 (the "2020 Share Plan").
The 2020 Share Plan specifically introduced a class of options termed Compensation Options, that may be awarded in lieu of fees as a method of conserving cash and reducing costs in the Company. The options exercised by Thomas Mackay were Compensation Options awarded in lieu of fees almost five years ago and are due to expire in less than three months. The exercise will provide £36,000 of additional funding to the Company, which will be used for general working capital purposes.
Applications will be made to the Financial Conduct Authority ("FCA") and the London Stock Exchange for the Option Shares to be admitted to the FCA's Official List (Equity Shares (transition)) and to trading on the main market of the London Stock Exchange ("Admission"). It is expected that Admission will become effective and that dealings will commence in the Option Shares at 8.00 a.m. (London time) on 26 October 2026. Following Admission, the enlarged share capital and the total voting rights of the Company will be 4,518,001,044. The Company does not hold any shares in treasury.
The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.
Director/PDMR Shareholding
The notification below is made in accordance with the Article 19 of the Market Abuse Regulation (EU) 596/2014, as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended.
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name
Thomas Mackay
2
Reason for the notification
a)
Position/status
Director
b)
Initial Notification Amendment
Initial Notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Aminex PLC
b)
LEI
635400CSEBJAYPUUFC95
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument,
type of
instrument
Identification code
Ordinary Shares of €0.001 each
IE0003073255
b)
Nature of the transaction
Exercise of Options and Sale of Ordinary Shares
c)
Price(s) and volume(s)
Options exercised: 6,000,000 Ordinary Shares at an exercise price of 0.60 pence each
Ordinary Shares sold: 6,000,000 at 1.824 pence each
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
14 October 2026
f)
Place of the transaction
London Stock Exchange
For further information:
Aminex PLC
+44 203 355 9909
Charles Santos, Executive Chairman
Knights Media & Public Relations
aminex@knightsmpr.com
Sabina Zawadzki
Davy
+353 1 679 6363
Brian Garrahy
Shard Capital
+44 20 7186 9952
Damon Heath
Axis Capital Markets
+44 203 026 0320
Richard Hutchison
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDIOEFEMSASEMSESS
